Welcome to our dedicated page for CARLSMED SEC filings (Ticker: CARL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Carlsmed, Inc. filings document the regulatory record of a commercial-stage medical technology company developing AI-enabled personalized spine surgery solutions. Recent 8-K filings report results of operations and financial condition, including furnished earnings releases tied to the company’s aprevo® platform, product activity and revenue outlook.
The company’s SEC materials also cover emerging growth company status, annual meeting and proxy governance matters, and capital-structure disclosures. Material-event filings include amendments to loan and security arrangements, credit facility terms, warrant-related disclosures and other financing matters relevant to Carlsmed’s public-company reporting.
CARLSMED, INC. (CARL) reported that Casey M. Tansey, identified as a ten percent owner, purchased 200,000 shares of common stock on July 24, 2025 in an open-market or private transaction at $15.00 per share. Following this transaction, Tansey is reported as holding 200,000 shares, with the stock held by Casey M. Tansey as noted in the footnote. The amendment corrects an earlier Form 4 that omitted this purchase, and no Rule 10b5-1 trading plan is reported.
CARLSMED, INC. (CARL) reported that Chief Operating Officer Jeffrey Bertolini received a grant of stock options for 50,000 shares of common stock on September 8, 2026. The options have an exercise price of $15.23 per share, expire on September 7, 2036, and vest starting after a one-year cliff from September 8, 2026, then in equal quarterly installments while he remains in service. No Rule 10b5-1 trading plan is reported for this grant.
CARLSMED, INC. (CARL) reported the initial equity holdings of Chief Operating Officer Jeffrey Bertolini. He directly holds 22,489 shares of Common Stock, which includes restricted stock units that vest in three equal annual installments beginning January 28, 2026, subject to his continued service. He also holds stock options to acquire 35,714, 22,402 and 6,068 shares of Common Stock at exercise prices of $15.00, $5.92 and $2.23 per share, expiring between November 12, 2034 and July 21, 2035, with portions already vested and the remainder vesting over time, contingent on continued service.
Carlsmed, Inc. (CARL) announced that its Board of Directors appointed Jeffrey (Jeff) Bertolini as Chief Operating Officer, effective September 8, 2026. He has held senior operations roles at Carlsmed since 2024 and previously at SI-BONE, NuVasive, and US Surgical.
Bertolini’s employment agreement includes a base salary that increases to $475,000 with a 60% target annual cash incentive opportunity. If his employment is terminated without cause or he resigns for good reason outside of a defined corporate-transaction window, he is eligible for 12 months of base-salary continuation, potential annual incentive payments, and up to 12 months of COBRA reimbursements. On September 8, 2026, he was also granted 50,000 stock options to purchase Carlsmed common stock.
Carlsmed, Inc., a Delaware-based medical technology company focused on AI-enabled personalized spine surgery solutions, has filed a shelf registration to offer up to $250,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time. The filing allows Carlsmed to access capital markets in multiple tranches, with specific terms and pricing for each issuance to be detailed in future prospectus supplements.
The company’s aprevo Technology Platform provides customized spinal implants and single-use instruments manufactured via a digital production system with a typical six-business-day lead time from surgeon plan approval to hospital delivery. Carlsmed’s capital structure authorizes 600,000,000 shares of common stock and 10,000,000 shares of preferred stock, with no preferred shares currently outstanding as of June 30, 2026. Its common stock trades on the Nasdaq Global Select Market under the symbol CARL, and the last reported share price was $13.99 on August 13, 2026. The company highlights existing investor registration rights, anti-takeover and forum-selection provisions, and outlines generic terms under which future debt securities and warrants may be issued.
Carlsmed, Inc., a medical technology company focused on AI‑enabled personalized spine surgery, reported higher revenue for the quarter ended June 30, 2026. Revenue was $18.9 million, up from $12.1 million a year earlier, and first‑half 2026 revenue reached $35.1 million versus $22.3 million.
Increased investment in research and development, sales and marketing, and general and administrative functions raised operating expenses to $25.6 million in Q2, leading to a net loss of $10.5 million for the quarter and $19.2 million for the first half. As of June 30, 2026, Carlsmed held $89.3 million in cash, cash equivalents, restricted cash, short‑term investments, and marketable securities and had $15.6 million outstanding under its term loan. The company continues U.S. commercialization of its aprevo lumbar and cervical implants and plans a full commercial launch of the corra Cervical Plating System by December 2026.
Carlsmed, Inc. reported strong growth for the quarter ended June 30, 2026, with revenue of $18.9 million, up 57% from $12.1 million a year earlier, driven by increasing adoption of its AI-enabled aprevo spine surgery solutions. Gross profit rose to $14.5 million and gross margin expanded to 76.8% from 73.4%, while trained surgeon users grew more than 60% year-over-year. The company highlighted growing volume across lumbar and cervical procedures, with aprevo cervical in its second full quarter of commercialization and contributing about 10% of quarterly revenue.
Operating expenses increased to $25.6 million from $15.4 million as Carlsmed invested in research and development, sales and marketing, and administrative capabilities, leading to a net loss of $10.5 million versus $6.8 million last year and adjusted EBITDA of ($8.6 million). Cash, restricted cash, short-term investments, and marketable securities totaled $89.3 million as of June 30, 2026. Management raised full‑year 2026 revenue guidance to a range of $74–$78 million, representing over 50% growth at the midpoint versus 2025 and slightly above the prior $72–$77 million range. The company also cited a recent CMS Inpatient Prospective Payment System ruling, effective October 1, 2026, that adds new MS‑DRG codes and provides favorable hospital reimbursement for inpatient aprevo lumbar procedures.
CARLSMED, INC. director Kevin C. O’Boyle received a grant of 13,698 shares of Common Stock as a stock award with no cash price per share. Following this grant, he directly holds 31,031 common shares. The award is structured as restricted stock units that each convert into one share upon vesting. These RSUs vest in full on the earlier of the day before Carlsmed’s 2027 annual meeting of stockholders or June 3, 2027, contingent on his continued service on the Board of Directors through that date.
Sidow Kevin reported acquisition or exercise transactions in this Form 4 filing.
CARLSMED, INC. director Kevin Sidow reported receiving an equity award in the form of 13,698 restricted stock units, each convertible into one share of Common Stock upon vesting. These RSUs vest in full on the earlier of the day before the company’s 2027 annual stockholder meeting or June 3, 2027, if he continues serving on the Board through that date. Following this grant, Sidow directly holds 73,264 shares of Common Stock, reflecting a routine, compensation-related increase in his equity stake.